Lantheus Holdings (LNTH) Cash from Investing Activities (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Cash from Investing Activities came in at $26.0 million in Q1 2026, up 140.78% year-on-year from $10.8 million in Q1 2025, and up 325.77% on a QoQ basis from -$11.5 million in Q4 2025.
Lantheus Holdings (LNTH) Cash from Investing Activities (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Cash from Investing Activities data on file, last reported at $26.0 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 140.78% year-over-year to $26.0 million in Q1 2026; TTM through Mar 2026 was -$537.5 million, a 193.37% decrease from a year earlier, with the FY2025 full-year figure at -$627.2 million, down 177.49% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $26.0 million, up from -$11.5 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for LNTH reached as high as $83.2 million in Q3 2023 and fell as low as -$319.5 million in Q3 2025.
- Historically, Cash from Investing Activities has averaged -$64.6 million across 5 years, with a median of -$20.7 million in 2023.
- Across the five-year window, Cash from Investing Activities plunged 5725.79% in 2022 and surged 1466.47% in 2023, its largest moves.
- Year by year, Cash from Investing Activities stood at -$264.7 million in 2022, then soared by 95.44% to -$12.1 million in 2023, then soared by 45.3% to -$6.6 million in 2024, then plunged by 74.34% to -$11.5 million in 2025, then jumped by 325.77% to $26.0 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were $26.0 million in Q1 2026, -$11.5 million in Q4 2025, and -$319.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.55 Bn | 87.69 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.45 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.47 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Lantheus Holdings | 6.98 Bn | 6.48 Bn | 230.92 Mn | 25.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.99 Mn |
| Mar 31, 2026 | 25.99 Mn |
| Dec 31, 2025 | -11.51 Mn |
| Dec 31, 2025 | -11.51 Mn |
| Sep 30, 2025 | -319.47 Mn |
| Sep 30, 2025 | -319.47 Mn |
| Jun 30, 2025 | -232.47 Mn |
| Jun 30, 2025 | -232.47 Mn |
| Mar 31, 2025 | -63.72 Mn |
| Mar 31, 2025 | -63.72 Mn |
| Dec 31, 2024 | -6.60 Mn |
| Dec 31, 2024 | -6.60 Mn |
| Sep 30, 2024 | -67.80 Mn |
| Sep 30, 2024 | -67.80 Mn |
| Jun 30, 2024 | -45.09 Mn |
| Jun 30, 2024 | -45.09 Mn |
| Mar 31, 2024 | -106.53 Mn |
| Mar 31, 2024 | -106.53 Mn |
| Dec 31, 2023 | -12.07 Mn |
| Dec 31, 2023 | -12.07 Mn |